The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
NCT ID: NCT01277237
Last Updated: 2014-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
50 participants
INTERVENTIONAL
2010-09-30
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease
NCT00819338
Effect of Omega-3 PUFA Supplementation in NAFLD Patients
NCT00230113
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
NCT01285362
The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients
NCT00758927
Effect of Omega 3 Fatty Acids on Vascular Function
NCT01888211
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Omacor
Omacor
Active comparator: omacor 4g/day
Lactose tablet
lactose tablet
placebo: lactose tablet 4g/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Omacor
Active comparator: omacor 4g/day
lactose tablet
placebo: lactose tablet 4g/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* fatty infiltration on ultrasound
* abnormal serum liver function tests.
Exclusion Criteria
* the prescription of medication which would cause non-alcoholic fatty liver - disease (e.g. tamoxifen)
* already taking supplementary fish oil
* alcohol intake of \>20g/day for women, \>40g/ day for men
* known allergy to fish oil
* on anticoagulants (antiplatelets are permitted)
* severe heart failure (NYHA class IV)
* pregnancy/ lactation
* age under 18 years.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NHS Lothian
OTHER_GOV
University of Edinburgh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter C Hayes, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Royal Infirmary of Edinburgh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Infirmary of Edinburgh
Edinburgh, Lothian, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-008275-34
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
Edin2008-008275-34
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.